Anteris Technologies Global Corp. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
AVR Nasdaq 3850 anteristech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Anteris Technologies Global Corp.

Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation - May 13th, 2026 2:00 pm
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors - May 13th, 2026 6:39 am
Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy - May 12th, 2026 7:33 pm
Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push - May 12th, 2026 5:43 pm
Anteris Announces Results for the First Quarter of 2026 - May 12th, 2026 5:00 pm
Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances - May 6th, 2026 7:45 pm
Anteris treats first US patients in DurAVR pivotal trial - May 6th, 2026 7:45 pm
Anteris Technologies enrolls First US patients in global PARADIGM trial for DurAVR heart valve - May 6th, 2026 11:40 am
Small Cap Watch: Small Ordinaries edges higher as company news flow continues - May 5th, 2026 6:11 pm
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial - May 5th, 2026 4:00 am
Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial - Apr 28th, 2026 4:00 am
A new valve, a new playbook: How Anteris is trying to reshape a $10B heart market - Apr 1st, 2026 9:47 pm
Truffle Capital Unveils the First Edition of the Truffle MedTech 10 - Mar 18th, 2026 1:00 am
Anteris Technologies Global CEO Touts DurAVR Redesign, Durability Claims and TAVR Market Strategy - Mar 12th, 2026 6:35 am
Anteris Technologies Global Highlights DurAVR TAVR Data, PARADIGM Pivotal Trial Plans at TD Cowen Conference - Mar 5th, 2026 3:03 am
Anteris reports US$77.8m 2025 net operating cash outflow as PARADIGM trial gets underway - Feb 26th, 2026 4:41 pm
Anteris Reports 2025 Financial Results and Provides Corporate Update - Feb 26th, 2026 4:00 pm
Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays - Feb 23rd, 2026 4:30 am
Anteris Technologies price target lowered to $15 from $20 at Lake Street - Jan 24th, 2026 7:01 am
Retail investors who hold 25% of Anteris Technologies Global Corp. (ASX:AVR) gained 41%, institutions profited as well - Jan 23rd, 2026 1:17 pm